RORC

Nuclear receptor ROR-gamma · P51449 · RORC on Sugi Atlas →

287,075 patent compounds predicted against RORC, 145,484 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL174114 SCHEMBL174114 1.00 20/20
SCHEMBL174479 SCHEMBL174479 1.00 20/20
SCHEMBL174641 SCHEMBL174641 1.00 20/20
SCHEMBL175040 SCHEMBL175040 1.00 20/20
SCHEMBL175183 SCHEMBL175183 1.00 20/20
SCHEMBL174561 SCHEMBL174561 0.92 20/20
SCHEMBL175072 SCHEMBL175072 0.89 20/20
SCHEMBL175194 SCHEMBL175194 0.86 20/20
SCHEMBL174084 SCHEMBL174084 0.85 20/20
SCHEMBL174154 SCHEMBL174154 0.85 20/20
SCHEMBL175214 SCHEMBL175214 0.85 20/20
SCHEMBL174203 SCHEMBL174203 0.83 20/20
SCHEMBL174639 SCHEMBL174639 0.83 20/20
SCHEMBL175182 SCHEMBL175182 0.81 20/20
SCHEMBL167597 SCHEMBL167597 0.79 20/20
SCHEMBL174891 SCHEMBL174891 0.78 20/20
SCHEMBL174439 SCHEMBL174439 0.81 19/20
SCHEMBL168480 SCHEMBL168480 0.57 17/20
SCHEMBL174165 SCHEMBL174165 0.72 16/20
SCHEMBL17126 SCHEMBL17126 0.54 16/20

Clinical trials — most relevant to RORC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR PHASE2/PHASE3UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Prednisolone Trial in Children Younger Than 4 Years PHASE3COMPLETED
Latency in Pulmonary Tuberculosis PHASE3COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Mechanistic Study of Indigo Naturalis in Treating Psoriasis PHASE2COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis PHASE2ACTIVE_NOT_RECRUITING
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies PHASE1UNKNOWN
Meclizine for Hepatocellular Carcinoma PHASE1COMPLETED
Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission? EARLY_PHASE1UNKNOWN
A Study of RD14-01 in Patients With Advanced Solid Tumors EARLY_PHASE1UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis. nanCOMPLETED
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
Gene Expression in Chronic Venous Leg Ulcers nanUNKNOWN
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients nanUNKNOWN
Effect of Liraglutide on Clock Genes nanUNKNOWN
Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes nanCOMPLETED
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Immune Benefits From Mushroom Consumption nanCOMPLETED
The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation nanCOMPLETED
Gut Microbiome Analysis in Organ Transplant Recipient nanNOT_YET_RECRUITING
Basal Instincts: Towards Better Understanding of Basal Cell Function in Chronic Rhinosinusitis With Nasal Polyps nanRECRUITING
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity nanCOMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
The Role of Regulatory T Cell in Patients With Type 1 Diabetes Mellitus nanUNKNOWN
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT nanCOMPLETED
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases nanNOT_YET_RECRUITING
Inflammatory Bowel Diseases (IBD) Cannabis Registry nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RORC binder may also engage these)

ProteinNameSimilarity
Q5RAP4 1.000 Q5RAP4 →
P51450 1.000 P51450 →
NR1H3 Oxysterols receptor LXR-alpha 0.996 landscape →
Q9XSB5 0.996 Q9XSB5 →
Q9XSW2 0.996 Q9XSW2 →
Q5E9B6 0.996 Q5E9B6 →
Q9TU15 0.995 Q9TU15 →
Q62685 0.995 Q62685 →
P51448 0.995 P51448 →
P50241 0.995 P50241 →
O13012 0.995 O13012 →
P12813 0.995 P12813 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.994 landscape →
Q9W6M2 0.994 Q9W6M2 →
P57717 0.994 P57717 →
P57753 0.994 P57753 →
Q9IAL9 0.994 Q9IAL9 →
P57782 0.994 P57782 →
Q9W669 0.994 Q9W669 →
P50569 0.994 P50569 →
NR1H2 Oxysterols receptor LXR-beta 0.994 landscape →
P33242 0.993 P33242 →
Q9QXZ7 0.993 Q9QXZ7 →
Q9YHZ7 0.993 Q9YHZ7 →
P50242 0.993 P50242 →
O97716 0.993 O97716 →
F1QLY4 0.993 F1QLY4 →
P06211 0.993 P06211 →
Q9YH33 0.993 Q9YH33 →
THRA Thyroid hormone receptor alpha 0.993 landscape →